Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: bevacizumab|BIOLOGICAL: pegfilgrastim|DRUG: cyclophosphamide|DRUG: doxorubicin hydrochloride|DRUG: paclitaxel albumin-stabilized nanoparticle formulation|OTHER: flow cytometry|OTHER: immunoenzyme technique|OTHER: immunologic technique|OTHER: laboratory biomarker analysis|PROCEDURE: adjuvant therapy|PROCEDURE: immunoscintigraphy
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborators: National Cancer Institute (NCI)